Literature DB >> 16926424

Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells.

Asna A Siddiqui1, Robin J Shattock, Thomas S Harrison.   

Abstract

Cryptococcus neoformans is a frequent cause of meningoencephalitis in immunosuppressed individuals. To better understand the mechanisms of a protective immune response to C. neoformans, a long-term in vitro model of human immune control of cryptococcal infection was developed. Peripheral blood mononuclear cells (PBMC) prestimulated with heat-killed C. neoformans significantly restricted the growth of C. neoformans after a subsequent live infection compared to that with unstimulated PBMC. Live infection with encapsulated C. neoformans was controlled for as long as 10 days, while infection with acapsular organisms could sometimes be eradicated. During immune control, fungal cells were both intracellular and extracellular within aggregates of mononuclear phagocytes and lymphocytes. Optimal immune control depended on the presence of both CD4+ and CD8+ T cells. Immune control of cryptococcal growth was more effective following prestimulation with acapsular compared with encapsulated organisms. Prestimulation with acapsular organisms was associated with a significant and prolonged increase in interleukin-6 (IL-6) production compared with prestimulation with encapsulated C. neoformans. Addition of IL-6 and depletion of CD25+ T cells prior to prestimulation and infection with encapsulated organisms resulted in reductions in cryptococcal growth that reached borderline statistical significance. Depletion of CD25+ T cells significantly reduced cryptococcal growth in wells with unstimulated PBMC. The results demonstrate an association between high levels of IL-6 and resistance to infection and, through suppression of IL-6 release, an additional mechanism whereby the cryptococcal capsule subverts a protective immune response. Further work is required to clarify the mechanism of action of IL-6 in this setting and any interaction with regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926424      PMCID: PMC1594853          DOI: 10.1128/IAI.00661-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

Review 1.  Natural regulatory T cells in infectious disease.

Authors:  Yasmine Belkaid; Barry T Rouse
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

2.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Involvement of mannose receptor in cytokine interleukin-1beta (IL-1beta), IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages.

Authors:  Y Yamamoto; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

4.  Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation.

Authors:  Donatella Pietrella; Cristina Corbucci; Stefano Perito; Giovanni Bistoni; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.

Authors:  Asna A Siddiqui; Annemarie E Brouwer; Vannaporn Wuthiekanun; Shabbar Jaffar; Robin Shattock; Diane Irving; Joanna Sheldon; Wirongrong Chierakul; Sharon Peacock; Nicholas Day; Nicholas J White; Thomas S Harrison
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

6.  Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components.

Authors:  D Delfino; L Cianci; E Lupis; A Celeste; M L Petrelli; F Curró; V Cusumano; G Teti
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 7.  Cryptococcus neoformans: a sugar-coated killer with designer genes.

Authors:  John R Perfect
Journal:  FEMS Immunol Med Microbiol       Date:  2005-09-01

8.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis.

Authors:  P A Robinson; M Bauer; M A Leal; S G Evans; P D Holtom; D A Diamond; J M Leedom; R A Larsen
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

9.  Enhanced sensitivity of tumor necrosis factor/lymphotoxin-alpha-deficient mice to Cryptococcus neoformans infection despite increased levels of nitrite/nitrate, interferon-gamma, and interleukin-12.

Authors:  N Rayhane; O Lortholary; C Fitting; J Callebert; M Huerre; F Dromer; J M Cavaillon
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

10.  Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form.

Authors:  C E Cross; G J Bancroft
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more
  16 in total

1.  Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome.

Authors:  David R Boulware; Shulamith C Bonham; David B Meya; Darin L Wiesner; Gregory S Park; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

Review 2.  Hypercapnia: a nonpermissive environment for the lung.

Authors:  István Vadász; Rolf D Hubmayr; Nicolás Nin; Peter H S Sporn; Jacob I Sznajder
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-12       Impact factor: 6.914

3.  Elevated CO2 selectively inhibits interleukin-6 and tumor necrosis factor expression and decreases phagocytosis in the macrophage.

Authors:  Naizhen Wang; Khalilah L Gates; Humberto Trejo; Silvio Favoreto; Robert P Schleimer; Jacob I Sznajder; Greg J Beitel; Peter H S Sporn
Journal:  FASEB J       Date:  2010-02-24       Impact factor: 5.191

4.  Macrophage autophagy in immunity to Cryptococcus neoformans and Candida albicans.

Authors:  André Moraes Nicola; Patrícia Albuquerque; Luis R Martinez; Rafael Antonio Dal-Rosso; Carolyn Saylor; Magdia De Jesus; Joshua D Nosanchuk; Arturo Casadevall
Journal:  Infect Immun       Date:  2012-06-18       Impact factor: 3.441

5.  Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice.

Authors:  Matthew Marks; Tamika Burns; Maria Abadi; Beza Seyoum; Justin Thornton; Elaine Tuomanen; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.

Authors:  Krishanthi S Subramaniam; Kausik Datta; Matthew S Marks; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

Review 8.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

9.  IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status.

Authors:  Krishanthi Subramaniam; Brian Metzger; Lawrence H Hanau; Alice Guh; Lisa Rucker; Sheila Badri; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

10.  Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species.

Authors:  Teske Schoffelen; Maria-Teresa Illnait-Zaragozi; Leo A B Joosten; Mihai G Netea; Teun Boekhout; Jacques F Meis; Tom Sprong
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.